Scientific Programme EMUC18, Amsterdam, 8 11 November Friday, 9 November

Transcription

1 Scientific Programme EMUC18, Amsterdam, 8 11 November 2018 Friday, 9 November 08:30-08:40 Welcome and introduction Medical oncologist Manuela Schmidinger, Vienna (AT) - ESMO Radiation oncologist Peter Hoskin, Northwood (GB) - ESTRO Urologist Hein Van Poppel, Leuven (BE) - EAU 08:40-10:30 Prostate cancer management: Implementation without good evidence? Chairs: Medical oncologist - Maria De Santis, Coventry (GB) Urological researcher - Kerstin Junker, Homburg (DE) Urologist - James N Dow, Aberdeen (GB) Radiation oncologist Bradley Pieters, Amsterdam (NL) 08:40-08:50 Functional imaging for recurrent disease Nuclear medicine - Stefano Fanti, Bologna (IT) 08:50-09:00 Digital GU pathology Pathologist - Rodolfo Montironi, Ancona (IT) 09:00-09:10 High tech radiotherapy Radiation oncologist - Alberto Bossi, Villejuif (FR) 09:10-09:20 Salvage surgery for recurrent disease Urologist - Steven Joniau, Leuven (BE) 09:20-09:30 Sequencing of novel therapies in urogenital malignancies Medical oncologist - Maria De Santis, Coventry (GB) 09: How to generate good evidence for 2025? Biostatistician - Mahesh Parmar, London (GB) :30 Discussion Urologist - James N Dow, Aberdeen (GB) Coffee break and poster viewing 11:00-12:25 Controversies and contradictions in staging of prostate cancer Chairs: Pathologist - Mahul Amin, Los Angeles (US) Urologist - Igle-Jan De Jong, Groningen (NL) Urologist - Derya Tilki, Hamburg (DE) 11:00-11:20 Predictive statistics applied to diagnosis Statistician - Andrew Vickers, New York (US) 11:20-12:25 Multidisciplinary case discussion Case presenter: Urologist Guillaume Ploussard, Toulouse (FR) Pathologist - Mahul Amin, Los Angeles (US) Nuclear medicine - Arturo Chiti, Rozzano (IT) Radiation oncologist - Berardino De Bari, Besancon (FR) Urologist - Jeffrey Karnes, New York (US) Medical oncologist - Stephane Oudard, Paris (FR) Radiologist Philippe Puech, Lille (FR)

2 12:25-12:45 Update on consensus meetings Chairs: Medical oncologist - Karim Fizazi, Villejuif (FR) Pathologist Antonio Lopez-Beltran, Lisbon (PT) Urologist Jeroen Van Moorselaar, Amsterdam (NL) 12:25-12:35 Update on EAU Prostate Cancer Center consensus meeting Urologist Peter Albers, Dusseldorf (DE) 12:35-12:45 ECCO-ERQCC Urologist - Maurizio Brausi, Modena (IT) Radiation oncologist - Peter Hoskin, Northwood (GB) 12:45-14:00 Lunch break and poster viewing (13:00 14:00 Industry session) 14:00-15:30 Immunotherapy: Evolving paradigms in GU cancers Chairs: Pathologist - Maurizio Colecchia, Milan (IT) Urologist - Igle-Jan De Jong, Groningen (NL) Radiation oncologist Ananya Choudhury, Manchester (GB) Urologist Ashsish Kamat, Houston (US) 14:00 14:30 Immunotherapy for all patients as first line in kidney cancer? YES Medical oncologist Laurence Albiges, Villejuif (FR) NO Medical oncologist Manuela Schmidinger, Vienna (AT) 14:30 14:45 Discussion and questions from the audience 14:45 14:55 Non metastatic MIBCa: Which role for immunotherapy? Urologist Andrea Necchi, Milan (IT) 14:55-15:10 Metastatic MIBC: When should immunotherapy be used? Oncologist Aristotelis Bamias, Athens (GR) 15:10-15:30 Discussion and questions from audience 15:30 16:00 Coffee break and poster viewing 16:00 17:30 Kidney cancer in the frail patient Chairs: Urologist - Axel Bex, Amsterdam (NL) Urological researcher - Kerstin Junker, Homburg (DE) Pathologist - Gladell Paner, Chicago (US) 16:00-16:20 How to identify the frail patient? Urologist - Umberto Capitanio, Milan (IT) 16:20-17:30 Multidisciplinary case discussion Clinical case by YAU members Medical oncologist Joaquim Bellmunt, Boston (US) Nuclear medicine - Karolien Goffin, Leuven (BE) Radiation oncologist Piet Ost, Ghent (BE) Urologist Brunolf Lagerfeld, Amsterdam (NL) Pathologist - Gladell Paner, Chicago (US) Radiologist - Harriet Thoeny, Berne (CH) (17:45-18:45 Industry session) Urologist - Karim Bensalah, Rennes (FR) Urologist - Maria Carmen Mir Maresma, Valencia (ES)

3 Saturday, 10 November 08:00-10:00 New trials update: What we need to know Chairs: Biostatistician - Laurence Collette, Brussels (BE) Urologist - Matthew Cooperberg, San Francisco (US) Urologist - Stephen Boorjian, Rochester (US) Radiation oncologist - Alberto Bossi, Villejuif (FR) 08:00-08:20 Early hormonal manipulation in M0 CRPC Speaker: Medical oncologist - Karim Fizazi, Villejuif (FR) Discussant: Urologist - Thomas Steuber, Hamburg (DE) 08:20-08:40 CARMENA trial Speaker: Urologist - Arnaud Mejean, Paris (FR) Discussant: Urologist Axel Bex, Amsterdam (NL) 08:40-09:00 POUT trial Speaker: Clinical oncologist - Alison Birtle, Preston (GB) Discussant: Urologist - Shahrokh Shariat, Vienna (AT) 09:00-09:20 STAMPEDE trial Speaker: Radiation oncologist - Nicholas James, Birmingham (GB) Discussant: Urologist - Noel Clarke, Manchester (GB) 09:20 09:40 PRECISION trial Speaker: Urologist - Caroline Moore, London (GB) Discussant: Urologist - Georg Salomon, Hamburg (DE) 09:40 10:00 HORRAD trial Speaker: Urologist - George van Andel, Amsterdam (NL) Discussant: Radiation oncologist Gert De Meerleer, Leuven (BE) 10:00-10:30 Coffee break and poster viewing 10:30 11:00 Report from new consensus projects Chairs: Radiation oncologist Olivier Chapet, Pierre Bénite (FR) Medical oncologist - Cora Sternberg, Rome (IT) Hein Van Poppel, Leuven (BE) EAU 10: EAU-ESMO Bladder Cancer consensus report Urologist - Fred Witjes, Nijmegen (NL) 10:45-11:00 Highlights of Active Surveillance consensus meeting in PCa Urologist - Monique Roobol, Rotterdam (NL) 11:00 12:00 New developments in prostate cancer evaluation Chairs: Pathologist - Rodolfo Montironi, Ancona (IT) Radiologist - Harriet Thoeny, Berne (CH) Urologist - Henk Van der Poel, Amsterdam (NL) Radiation oncologist - Carl Salembier, Brussels (BE) 11:00-11:25 Everything in prostate cancer pathology you were afraid to ask Speaker: Pathologist - Jonathan I. Epstein, Baltimore (US) Discussant: Urologist - Alberto Briganti, Milan (IT) 11:25-11:50 Radiomics: Images are more than pictures

4 Speaker: Radiation oncologist Philippe Lambin, Maastricht (NL) Discussant: Urologist - Jochen Walz, Marseille (FR) 11:50 12:00 Discussion 12:00 12:40 Oral presentation of the 6 best abstracts 40 min Chairs: Clinical oncologist - Jan Oldenburg, Oslo (NO) Urologist Theo De Reijke, Amsterdam (NL) Radiation oncologist Philip Poortmans, Paris (FR) 12:40-14:00 Lunch break and poster viewing (13:00-14:00 Industry session) 14:00-16:00 BCG refractory disease: Is cystectomy avoidable? Chairs: Urologist - Marek Babjuk, Prague (CZ) Medical oncologist - Cora Sternberg, Rome (IT) Radiation oncologist Robert Huddart, Sutton (GB) 14:00-14:15 Mechanisms of action and of resistance to BCG Urologist George Thalmann, Berne (CH) 14:15-14:30 Pathological variants and predictive markers of BCG response Pathologist Antonio Lopez-Beltran, Lisbon (PT) 14:30-14:45 Modified BCG trial (SAKK) Urologist - Cyrill Rentsch, Basel (CH) 14:45-15:00 Immunotherapy in NMIBCa Urologist - Morgan Roupret, Paris (FR) 15: Gene therapy Urologist - Colin Dinney, Houston (US) 15:15-15:30 Discussion 15:30-16:00 Case presentation Urologist - Evanguelos Xylinas, Paris (FR) 16:00-16:30 Coffee break and poster viewing 16:30-17:30 Nightmare session: It could happen to you Chairs: Pathologist - Ferran Algaba, Barcelona (ES) Medical oncologist Susanne Osanto, Leiden (NL) Urologist - Shahrokh Shariat, Vienna (AT) Radiation oncologist Philip Poortmans, Paris (FR) 16:30 16:45 The urologist s nightmare Urologist Tim O-Brien, London (GB) 16:45-17:00 The radiation oncologist s nightmare Radiation oncologist - Gert De Meerleer, Leuven (BE) 17:00-17:15 The medical oncologist s nightmare Medical oncologist - Thomas Powles, London (GB) 17:15-17:30 The pathologist s nightmare Pathologist - Rodolfo Montironi, Ancona (IT) ( Industry session)

5 Sunday, 11 November 08:30-08:45 Announcement 3 best unmoderated posters Chairs: Clinical oncologist - Jan Oldenburg, Oslo (NO) Radiologist - Raymond Oyen, Leuven (BE) Radiation oncologist - Bradley Pieters, Amsterdam (NL) Urologist Michiel Sedelaar, Nijmegen (NL) 08:45-09:00 EAU Research Foundation Urologist Anders Bjartell, Malmö (SE) 09: Current dilemmas in the management of metastatic prostate cancer Chairs: Urologist Francesco Montorsi, Milan (IT) Radiation oncologist Peter Hoskin, Northwood (GB) 09:00-09:15 Cross-talk between primary and metastatic sites Pathologist - Mark Rubin, New York (US) 09:15 09:30 Cell free DNA in blood: The best source for response prediction? Molecular biologist - Alexander Wyatt, Vancouver (CA) 09:30-09:45 Why some patients get only oligo-metastatic disease? Geneticist - Arul Chinnaiyan, Michigan (US) 09:45 10:05 Metastasis directed therapy for oligo-metastatic recurrence YES Radiation oncologist - Piet Ost, Ghent (BE) NO Urologist Philip Cornford, Liverpool (GB) 10:05 10:25 Selected patients with castration sensitive PCa only require ADT YES Medical oncologist - Karim Fizazi, Villejuif (FR) NO Urologist - Nicolas Mottet, Saint-Étienne (FR) 10:25-10:45 What is the optimal combination therapy? Abiraterone or docetaxel? Or both? 10:45-11:05 Discussion 11:05 11:50 Take home messages 11:05 11:15 Pathologist - Rodolfo Montironi, Ancona (IT) 11:15 11:25 Radiation oncologist - Anne Kiltie, Oxford (GB) 11:25 11:35 Urologist - Evanguelos Xylinas, Paris (FR) 11:35 11:45 Radiologist - Harriet Thoeny, Berne (CH) 11:45 11:55 Medical oncologist Laurence Albiges, Villejuif (FR) 11:55 12:00 Closing remarks Medical oncologist Manuela Schmidinger, Vienna (AT) - ESMO Radiation oncologist - Peter Hoskin, Northwood (GB) - ESTRO Urologist - Hein Van Poppel, Leuven (BE) - EAU